Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Background: Glioblastoma (GBM) is a cancer of the brain. Current survival rates for people with GBM are poor; survival ranges from 5.2 months to 39 months. Most tumors come back within months or years after treatment, and when they do, they are worse: Overall survival drops to less than 10 months. No standard treatment exists for people whose GBM has returned after radiation therapy. Objective: To find a safe schedule for using radiation to treat GBM tumors that returned after initial radiation treatment. Eligibility: People aged 18 years and older with grade 4 GBM that returned after initial radiation treatment. Design: Participants will be screened. They will have a physical exam with blood tests. A sample of tumor tissue may be collected. Participants will undergo re-irradiation planning: They will wear a plastic mask over their head during imaging scans. These scans will pinpoint the exact location of the tumor. This spot will be the target of the radiation treatments. Participants will undergo radiation treatment 4 times per week. Some people will have this treatment for 3 weeks, some for 2 weeks, and some for 1 week. Blood tests and other exams will be repeated at each visit. Participants will complete questionnaires about their physical and mental health. They will answer these questions before starting radiation treatment; once a week during treatment; and at intervals for up to 3 years after treatment ends. Participants will have follow-up visits 1 month after treatment and then every 2 months for 6 months. Follow-up clinic visits will continue up to 3 years. Follow-ups by phone or email will continue an additional 2 years.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Rozpoznany glejak mózgu (stopień 4) lub glejak wtórny, który wrócił po wcześniejszym leczeniu radiacyjnym
- •Wiek 18 lat i więcej
- •Ogólny stan zdrowia pozwalający na leczenie (skala sprawności >= 70%)
- •Wcześniejsze napromienianie mózgu w celach leczniczych
- •Wystarczająca funkcja krwi (liczba neutrofili >= 1000/μL, płytki >= 100 000/μL)
- •Osoby w wieku rozrodczym muszą stosować skuteczną antykoncepcję przez 6 miesięcy od końca leczenia
- •Możliwość wykonania rezonansu magnetycznego (MRI) z kontrastem
- •Świadoma zgoda pacjenta na udział w badaniu
✗ Disqualifies
- •Chemioterapia bewacyzumabem w ciągu 2 tygodni (chyba że z powodu progresji nowotworu)
- •Temozolomid w ciągu 2 tygodni
- •Chemioterapia cytostatyczna w ciągu 3 tygodni
- •Niemożność wykonania MRI lub przyjęcia kontrastu
- •Inne leczenie radiacyjne w ciągu 12 miesięcy przed badaniem
- •Wcześniejsza terapia NovaKure TTF, waflem Gliadel lub GammaTile
- •Dodatni test ciążowy (dla osób mogących zajść w ciążę)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 120 Years
- Last updated (source)
- July 14, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
National Institutes of Health Clinical Center
Bethesda, United States
Trial contact
Rukayat O Salau
Peter GK Mathen, M.D.
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/15/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.